Quidelortho Corp (QDEL)

$42.82

-1.17

(-2.66%)

Market is closed - opens 7 PM, 20 May 2024

Insights on Quidelortho Corp

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 744.0M → 709.7M (in $), with an average decrease of 2.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 7.0M → -1.70B (in $), with an average decrease of 24471.4% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 39.2% return, outperforming this stock by 90.2%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 78.1% return, outperforming this stock by 142.6%

Performance

  • $42.24
    $44.10
    $42.82
    downward going graph

    1.35%

    Downside

    Day's Volatility :4.21%

    Upside

    2.89%

    downward going graph
  • $37.78
    $90.45
    $42.82
    downward going graph

    11.77%

    Downside

    52 Weeks Volatility :58.23%

    Upside

    52.66%

    downward going graph

Returns

PeriodQuidelortho CorpSector (Health Care)Index (Russel 2000)
3 Months
-8.09%
0.8%
0.0%
6 Months
-37.31%
13.4%
0.0%
1 Year
-52.02%
11.4%
0.0%
3 Years
-64.48%
17.7%
-19.9%

Highlights

Market Capitalization
2.9B
Book Value
$49.52
Earnings Per Share (EPS)
-26.38
PEG Ratio
7.19
Wall Street Target Price
56.0
Profit Margin
-61.65%
Operating Margin TTM
2.32%
Return On Assets TTM
1.32%
Return On Equity TTM
-42.51%
Revenue TTM
2.9B
Revenue Per Share TTM
42.81
Quarterly Revenue Growth YOY
-16.0%
Gross Profit TTM
1.9B
EBITDA
620.3M
Diluted Eps TTM
-26.38
Quarterly Earnings Growth YOY
-0.77
EPS Estimate Current Year
2.15
EPS Estimate Next Year
3.43
EPS Estimate Current Quarter
0.39
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    71%Buy
    28%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Quidelortho Corp(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 30.78%

Current $42.82
Target $56.00

Company Financials

FY18Y/Y Change
Revenue
522.3M
↑ 88.05%
Net Income
74.2M
↓ 1008.55%
Net Profit Margin
14.2%
↑ 17.14%
FY19Y/Y Change
Revenue
534.9M
↑ 2.41%
Net Income
72.9M
↓ 1.7%
Net Profit Margin
13.63%
↓ 0.57%
FY20Y/Y Change
Revenue
1.7B
↑ 210.66%
Net Income
810.3M
↑ 1011.18%
Net Profit Margin
48.76%
↑ 35.13%
FY21Y/Y Change
Revenue
1.7B
↑ 2.22%
Net Income
704.2M
↓ 13.09%
Net Profit Margin
41.46%
↓ 7.3%
FY22Y/Y Change
Revenue
3.3B
↑ 92.28%
Net Income
548.7M
↓ 22.08%
Net Profit Margin
16.8%
↓ 24.66%
FY23Y/Y Change
Revenue
3.0B
↓ 8.34%
Net Income
-10.1M
↓ 101.84%
Net Profit Margin
-0.34%
↓ 17.14%
Q4 FY22Q/Q Change
Revenue
866.5M
↑ 10.55%
Net Income
30.3M
↑ 57.81%
Net Profit Margin
3.5%
↑ 1.05%
Q1 FY23Q/Q Change
Revenue
846.1M
↓ 2.35%
Net Income
48.8M
↑ 61.06%
Net Profit Margin
5.77%
↑ 2.27%
Q2 FY23Q/Q Change
Revenue
665.1M
↓ 21.39%
Net Income
-53.2M
↓ 209.02%
Net Profit Margin
-8.0%
↓ 13.77%
Q3 FY23Q/Q Change
Revenue
744.0M
↑ 11.86%
Net Income
-12.7M
↓ 76.13%
Net Profit Margin
-1.71%
↑ 6.29%
Q4 FY23Q/Q Change
Revenue
742.6M
↓ 0.19%
Net Income
7.0M
↓ 155.12%
Net Profit Margin
0.94%
↑ 2.65%
Q1 FY24Q/Q Change
Revenue
709.7M
↓ 4.43%
Net Income
-1.7B
↓ 24471.43%
Net Profit Margin
-240.38%
↓ 241.32%
FY18Y/Y Change
Total Assets
806.4M
↓ 13.78%
Total Liabilities
380.8M
↓ 46.23%
FY19Y/Y Change
Total Assets
910.9M
↑ 12.96%
Total Liabilities
351.0M
↓ 7.81%
FY20Y/Y Change
Total Assets
1.9B
↑ 105.43%
Total Liabilities
538.5M
↑ 53.39%
FY21Y/Y Change
Total Assets
2.4B
↑ 29.89%
Total Liabilities
501.0M
↓ 6.95%
FY22Y/Y Change
Total Assets
8.9B
↑ 264.38%
Total Liabilities
3.9B
↑ 682.66%
FY23Y/Y Change
Total Assets
8.6B
↓ 3.31%
Total Liabilities
3.6B
↓ 9.28%
Q4 FY22Q/Q Change
Total Assets
8.9B
↑ 2.31%
Total Liabilities
3.9B
↑ 1.58%
Q1 FY23Q/Q Change
Total Assets
8.8B
↓ 0.78%
Total Liabilities
3.8B
↓ 3.33%
Q2 FY23Q/Q Change
Total Assets
8.6B
↓ 2.69%
Total Liabilities
3.5B
↓ 6.41%
Q3 FY23Q/Q Change
Total Assets
8.5B
↓ 0.13%
Total Liabilities
3.6B
↑ 0.69%
Q4 FY23Q/Q Change
Total Assets
8.6B
↑ 0.28%
Total Liabilities
3.6B
↓ 0.43%
Q1 FY24Q/Q Change
Total Assets
6.7B
↓ 21.72%
Total Liabilities
3.4B
↓ 4.54%
FY18Y/Y Change
Operating Cash Flow
136.3M
↑ 392.06%
Investing Cash Flow
115.0M
↓ 126.62%
Financing Cash Flow
-244.1M
↓ 190.19%
FY19Y/Y Change
Operating Cash Flow
134.5M
↓ 1.36%
Investing Cash Flow
-27.2M
↓ 123.69%
Financing Cash Flow
-98.3M
↓ 59.73%
FY20Y/Y Change
Operating Cash Flow
629.8M
↑ 368.28%
Investing Cash Flow
-63.3M
↑ 132.55%
Financing Cash Flow
-130.3M
↑ 32.55%
FY21Y/Y Change
Operating Cash Flow
805.9M
↑ 27.96%
Investing Cash Flow
-319.5M
↑ 404.61%
Financing Cash Flow
-173.2M
↑ 32.93%
FY22Y/Y Change
Operating Cash Flow
885.3M
↑ 9.86%
Investing Cash Flow
-1.6B
↑ 414.57%
Financing Cash Flow
252.0M
↓ 245.52%
Q4 FY22Q/Q Change
Operating Cash Flow
169.4M
↓ 1846.39%
Investing Cash Flow
-59.3M
↑ 98.99%
Financing Cash Flow
-31.7M
↓ 74.84%
Q1 FY23Q/Q Change
Operating Cash Flow
188.9M
↑ 11.51%
Investing Cash Flow
-68.9M
↑ 16.19%
Financing Cash Flow
-59.6M
↑ 88.01%
Q2 FY23Q/Q Change
Operating Cash Flow
-30.6M
↓ 116.2%
Investing Cash Flow
-42.3M
↓ 38.61%
Financing Cash Flow
-99.7M
↑ 67.28%
Q3 FY23Q/Q Change
Operating Cash Flow
41.5M
↓ 235.62%
Investing Cash Flow
-21.3M
↓ 49.65%
Financing Cash Flow
-48.7M
↓ 51.15%

Technicals Summary

Sell

Neutral

Buy

Quidelortho Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Quidelortho Corp
Quidelortho Corp
9.57%
-37.31%
-52.02%
-64.48%
-23.03%
Stryker Corporation
Stryker Corporation
2.14%
15.69%
16.95%
31.58%
81.59%
Boston Scientific Corp.
Boston Scientific Corp.
9.75%
37.07%
39.06%
78.08%
100.19%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
2.51%
32.67%
-0.02%
-3.94%
54.77%
Abbott Laboratories
Abbott Laboratories
-2.78%
2.86%
-3.84%
-11.64%
37.38%
Medtronic Plc
Medtronic Plc
6.64%
14.32%
-4.0%
-32.19%
-1.88%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Quidelortho Corp
Quidelortho Corp
9.72
NA
7.19
2.15
-0.43
0.01
NA
49.52
Stryker Corporation
Stryker Corporation
38.17
38.17
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
62.65
62.65
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
38.42
38.42
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.67
32.67
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
27.19
27.19
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Quidelortho Corp
Quidelortho Corp
Buy
$2.9B
-23.03%
9.72
-61.65%
Stryker Corporation
Stryker Corporation
Buy
$127.2B
81.59%
38.17
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$109.6B
100.19%
62.65
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.3B
54.77%
38.42
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$182.4B
37.38%
32.67
13.96%
Medtronic Plc
Medtronic Plc
Buy
$113.7B
-1.88%
27.19
13.0%

Institutional Holdings

  • The Carlyle Group Inc

    18.63%
  • T. Rowe Price Investment Management,Inc.

    13.01%
  • Vanguard Group Inc

    7.24%
  • BlackRock Inc

    7.17%
  • RIMA MANAGEMENT, LLC

    4.48%
  • ArrowMark Colorado Holdings, LLC (ArrowMark Partners)

    3.98%

Company Information

QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.

Organization
Quidelortho Corp
Employees
7100
CEO
Mr. Michael S. Iskra
Industry
Health Technology

FAQs